Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Soleno Therapeutics (SLNO) EBIT Margin: 2013-2017

Historic EBIT Margin for Soleno Therapeutics (SLNO) over the last 3 years, with Jun 2017 value amounting to -296,800.00%.

  • Soleno Therapeutics' EBIT Margin fell 18205000.00% to -296,800.00% in Q2 2017 from the same period last year, while for Jun 2017 it was -926.52%, marking a year-over-year increase of 48662.00%. This contributed to the annual value of 81,242.86% for FY2024, which is N/A change from last year.
  • Latest data reveals that Soleno Therapeutics reported EBIT Margin of -296,800.00% as of Q2 2017, which was down 57,184.78% from -518.11% recorded in Q1 2017.
  • Soleno Therapeutics' EBIT Margin's 5-year high stood at 195.07% during Q2 2014, with a 5-year trough of -296,800.00% in Q2 2017.
  • Moreover, its 3-year median value for EBIT Margin was -1,370.45% (2015), whereas its average is -43,117.22%.
  • Its EBIT Margin has fluctuated over the past 5 years, first spiked by 1,007,358bps in 2016, then tumbled by 18,205,000bps in 2017.
  • Over the past 5 years, Soleno Therapeutics' EBIT Margin (Quarterly) stood at 180.42% in 2013, then tumbled by 10,088bps to 79.54% in 2014, then crashed by 153,178bps to -1,452.24% in 2015, then surged by 80,629bps to -645.95% in 2016, then plummeted by 18,205,000bps to -296,800.00% in 2017.
  • Its EBIT Margin was -296,800.00% in Q2 2017, compared to -518.11% in Q1 2017 and -645.95% in Q4 2016.